Trial Profile
Effect of switching from PDE-5 inhibitors to Riociguat in patients with pulmonary hypertension : a retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2017
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 11 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society